There are 360 resources available
135P - Camrelizumab plus chemotherapy as first-line therapy for NSCLC: a pooled analysis of two randomized phase 3 trials with extended follow-up
Presenter: Caicun Zhou
Session: Poster Display
18P - Systematic evaluation of published predictive gene expression signatures in pan-cancer patient cohorts treated with immune checkpoint inhibitors in a real-world setting
Presenter: Ahmad Tarhini
Session: Poster Display
19P - Effects of CTLA-4 Single Nucleotide Polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanoma
Presenter: Karlijn Joode
Session: Poster Display
137P - Tislelizumab Combined with Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB(N2) Potentially resectable Squamous Non-small-cell Lung Cancer (TACT)
Presenter: JIANZHEN SHAN
Session: Poster Display
21P - Peripheral pre-existing T-cell immunity as predictive biomarker in cancer immunotherapy for NSCLC patients
Presenter: Anastasia Xagara
Session: Poster Display
139P - The timing, dynamics, and co-occurrence of immune-related adverse events with a PD-L1 inhibitor in non-small cell lung cancer
Presenter: Katherine Smith
Session: Poster Display
22P - Mean platelet volume to lymphocyte ratio: a new biomarker predictive of response in patients treated with immunotherapy
Presenter: Hasan Yildirim
Session: Poster Display